Experienced in Pure Red Cell Aplasia

Peter R. Lang

Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Pure Red Cell Aplasia
Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Peter Lang practices in Tuebingen, Germany. Mr. Lang is rated as an Experienced expert by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Graft Versus Host Disease (GvHD), Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Transplant.

His clinical research consists of co-authoring 184 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pure Red Cell Aplasia.

Gender
Male

Locations

Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
Enrollment Status: Recruiting
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Phase 3
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Drug
Study Drug: ch14.18/CHO
Study Phase: Phase 2
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Enrollment Status: Terminated
Publish Date: October 21, 2022
Intervention Type: Procedure
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

184 Total Publications

Correction: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025.
Correction: GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025.
Journal: Klinische Padiatrie
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lang's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile